Medical/Pharmaceuticals
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
2023-01-05 00:00
3494
Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America's Largest Hospital
* Lunit signed a software license agreement with the Hospital Israelita Albert Einstein,Latin America's top medical institution, to provide its AI-based chest x-ray solution * Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Alber...
2023-01-04 21:20
3527
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...
2023-01-04 21:00
2684
Waterdrop and Jemincare Collaborate on the "Digital Service Platform for CKD Patients"
BEIJING, Jan. 4, 2023 /PRNewswire/ -- Waterdrop and Jemincare recently reached a cooperation, according to which both sides will jointly launch the "Digital Service Platform for CKD Patients". Featuring both online and offline service modules ranging from follow-up visits and consultation with do...
2023-01-04 21:00
3984
Sihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing
Accelerating the Layout of Diabetes and Complications HONG KONG, Jan. 4, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announc...
2023-01-04 15:52
4330
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...
2023-01-03 23:25
2692
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...
2023-01-03 22:24
1801
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study cleared for initiation in the US * Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. ...
2023-01-03 20:00
3591
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2023-01-03 14:10
2946
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...
2022-12-29 23:25
3667
Qilu Pharmaceutical Announces Progress of Clinical Study of QL1706, an Innovative Bifunctional Antibody
JINAN, China, Dec. 29, 2022 /PRNewswire/ -- In 2022, Qilu Pharmaceutical revealed the latest progress being made with several clinical studies involving its innovativebifunctional antibody, QL1706, at several international and Chinese academic conferences, including the American Association for C...
2022-12-29 14:32
2534
A Korean DTx Company LifeSemantics to Unveil the Redpill Breath Solution for Pulmonary Rehabilitation DTx at CES 2023
* LifeSemantics will participate in the Digital Healthcare section of CES 2023 and unveil theRedpill Breath Solution, a pulmonary rehabilitation DTx. * The company will open a booth at the Korean pavilion in Eureka Park and offer an opportunity to experience the solution. * LifeSemantics wil...
2022-12-28 22:00
3209
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask
HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the launch of N95 medical protect...
2022-12-28 21:00
3572
EOFlow Submits Application to the U.S. FDA for its Wearable Insulin Pump 'EOPatch'
* Plans to finalize its U.S. distribution strategy in 2023 * Aims to enter the U.S., the world's largest diabetes market, with its current disposable wearable insulin pump 'EOPatch' SAN JOSE, Calif. , Dec. 27, 2022 /PRNewswire/ -- EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a p...
2022-12-27 15:48
2604
GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development
SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ann...
2022-12-26 23:01
3492
CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in humans.
SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based inRochester, MN...
2022-12-26 21:00
4117
Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals
* Winlevi® is a first-in-class topical drug for the treatment of acne approved by U.S. FDA inAugust 2020. * It will reinforce our Proprietary Brand segment's dermatological franchise. SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited (" Hyphens Pharma", or the "Comp...
2022-12-23 17:00
3071
PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital
Will Support Rapid Expansion of PVmed's AI Cancer Treatment Product Portfolio GUANGZHOU, China, Dec. 22, 2022 /PRNewswire/ -- Perception Vision Medical Technologies Co., Ltd. (PVmed), a global artificial intelligence (AI) cancer treatment company, headquartered inGuangzhou, China, has secured US ...
2022-12-23 11:31
3477
Ubitus and Smart Surgery enable doctors to practice robotic surgery with VR streaming
TOKYO, Dec. 22, 2022 /PRNewswire/ -- Ubitus K.K. (hereinafter Ubitus), a world-leading metaverse solution provider, supports Smart Surgery Technology to roll out its VR driven surgery simulation application – Sim Surgery. Smart Surgery Technology successfully demonstrated this innovative product ...
2022-12-22 22:00
3975
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
Exploring Xanamem® and the "cortisol hypothesis" for more than 6 million Americans suffering from Alzheimer's Disease[1] SYDNEY, Dec. 22, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is pleased to announce receipt today of agreement from the US Food and Drug Administration (FDA) to...
2022-12-22 20:30
2903
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 273 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24